Thursday, April 2, 2026

The Ultimate Stress Test: Artemis II Through a Cardiologist’s Lens

As the world watches the Artemis II mission prepare to carry four astronauts around the Moon, most eyes are on the trajectory and the tech. But as a cardiologist, I’m looking at a different set of instruments: the four human hearts beating inside the Orion spacecraft.

For the first time in over 50 years, humans are leaving the protective "bubble" of Low Earth Orbit (LEO). This isn't just a leap for exploration; it’s the ultimate cardiovascular stress test. Here is how deep space challenges the most vital muscle in the body.

1. The Great Fluid Shift: "Puffy Head, Bird Legs"

In Earth’s gravity, our cardiovascular system works tirelessly to pump blood upward against gravity. The moment the Artemis II crew hits microgravity, that workload vanishes.

Without gravity to pull fluids down, blood and interstitial fluid migrate toward the chest and head. This cephalad fluid shift creates what we call the "puffy face, bird legs" look. For a cardiologist, this is a fascinating acute volume overload scenario. The heart initially perceives this as "too much fluid" and responds by increasing stroke volume, but over time, the body adjusts by reducing overall plasma volume by about 10% to 15%.

2. Cardiac Atrophy: Use It or Lose It

The heart is a muscle, and like any muscle, it adapts to its workload. In space, the heart doesn't have to work as hard to circulate blood. Research from the International Space Station has shown that the heart can actually change shape, becoming more spherical and losing muscle mass (atrophy) during extended missions.

While Artemis II is a relatively short 10-day mission, it serves as a critical baseline for the longer lunar stays to come. We are watching to see how the heart handles the rapid transition from the high-G forces of launch to the "lazy" pumping requirements of deep space.

3. The Wild Card: Deep Space Radiation

This is where Artemis II differs from missions to the ISS. Once the crew leaves the Van Allen radiation belts, they are exposed to Galactic Cosmic Rays (GCRs) and solar particle events.

From a clinical perspective, space radiation is a known "accelerator" of cardiovascular aging. It can damage the endothelial lining of blood vessels, potentially speeding up atherosclerosis (hardening of the arteries) and causing oxidative stress. Artemis II is a vital data-gathering mission to help us understand how to protect future Mars-bound travelers from radiation-induced heart disease.

4. Heart Health on a Chip

One of the most exciting aspects of this mission is the AVATAR (A Virtual Astronaut Tissue Analog Response) investigation. NASA is using "organ-on-a-chip" technology—essentially tiny 3D cultures of the astronauts' own cells—to monitor how their specific heart tissue reacts to the unique stressors of deep space in real-time.

> Cardiologist’s Note: This isn't just for space. Understanding how hearts "age" or stiffen in microgravity helps us treat sedentary patients and those with heart failure right here on Earth.

The Return: Orthostatic Intolerance

The mission doesn't end when the capsule splashes down. When the crew returns to Earth’s 1G environment, gravity immediately pulls that blood back down to their legs. Because their hearts have spent 10 days "slacking off" and their blood volume is lower, many astronauts experience orthostatic intolerance—the inability to stand without feeling faint.

Final Thoughts

Artemis II is more than a lunar flyby; it’s a clinical trial for the future of humanity. As we push further into the cosmos, our understanding of the heart must evolve. We aren't just sending pilots and scientists to the Moon; we are sending the most complex, adaptive, and vulnerable biological pump ever designed.

Stay tuned as we follow the vitals of the Artemis II crew. The heartbeat of exploration has never been louder.

For more updates on the intersection of medicine and space, visit NASA’s Human Research Program.


Foundayo: A New Oral GLP-1 Option for Obesity

Foundayo (orforglipron), from Eli Lilly, is the first FDA-approved daily oral GLP-1 receptor agonist pill for adults with obesity (BMI ≥30) or overweight (BMI ≥27) with weight-related conditions like hypertension or type 2 diabetes. 

Unlike injections or food-restricted orals, it offers flexible dosing anytime, boosting potential adherence in long-term weight management.

FDA Approval Highlights

Approved on April 1, 2026, Foundayo earned the fastest new molecular entity nod under the National Priority Voucher program—see FDA announcement and Eli Lilly press release. It's indicated with diet/exercise; shipping starts April 6 via LillyDirect.

Dosing and Titration Schedule

Foundayo starts low to minimize gastrointestinal side effects, titrating over weeks based on tolerance and response (max 17.2 mg daily).

WeekDose (mg)Notes
1-20.8Starting dose; take once daily
3-42.2Increase if tolerated
5-64.9Monitor for nausea
7-88.1Flexible timing
9+10.6-17.2Target/maintenance; adjust per response

Clinical Efficacy

Phase 3 ATTAIN-1 trial (n>4,500) showed 12.4% body weight loss (27 lbs average) on highest dose vs. 2% placebo at 72 weeks—detailed in NEJM publication

Improvements persisted; 65% achieved ≥10% loss.

Cardiometabolic Benefits

Foundayo reduced waist circumference, triglycerides, non-HDL cholesterol, systolic blood pressure, and hsCRP. TRIUMPH outcomes trial assesses MACE in ASCVD patients, aligning with GLP-1 class CV protection.

Safety Profile

GI effects (nausea 20-30%, diarrhea, vomiting) peak early and wane; similar to injectables. Warnings: thyroid C-cell tumors, pancreatitis, gallbladder issues. Avoid with other GLP-1s; monitor hypoglycemia with insulin.

Pricing and Access

OptionMonthly CostDetails
Commercial Insurance + Savings Card$25Most pay this via Lilly
Self-Pay (LillyDirect)$149 (0.8 mg) to $349 (17.2 mg)Tiered by dose
Medicare Part D~$50 by July 2026Expected post-negotiation


Clinical Implications

For cardiologists, Foundayo offers a patient-friendly GLP-1 to tackle obesity-driven CV risk. Its pill form may widen access beyond Zepbound users, with scalable manufacturing aiding global reach. Monitor adherence and titrate carefully.

Wednesday, April 1, 2026

Cardiologist’s Quick Guide to Today’s New GLP‑1 Pill: Foundayo

By Bishnu Subedi, MD, FACC

If you followed the morning headlines today, you already know: April 1, 2026, is not April Fool’s Day for GLP‑1 lovers. The FDA just approved Foundayo (orforglipron), Eli Lilly’s first oral GLP‑1 receptor agonist for obesity and overweight. As a cardiologist, I’m excited—because this is another tool in our kit to treat the real cardiovascular risk factor: excess weight.

What Foundayo Is (And Why Cardiologists Care)

Foundayo is a small‑molecule, once‑daily oral GLP‑1 agonist without a water or fasting requirement, which is a big deal for adherence. In trials, the highest dose (36 mg) drove roughly 11% average weight loss, with clinically meaningful weight reduction even at 6–12 mg. For patients with obesity, ASCVD, diabetes, or metabolic syndrome, that kind of change can meaningfully shift blood pressure, lipids, and long‑term risk.

Snapshot of Key GLP‑1 Agents (Including Today’s New Kid)

For cardiology practice, here’s a super‑short table of the main GLP‑1–based players you’ll see in clinic, including Foundayo:

Drug (Brand)GenericRouteFrequencyCompanyMain Use
OzempicsemaglutideSCWeeklyNovo NordiskT2D ± CV risk reduction
WegovysemaglutideSC or oralWeekly or dailyNovo NordiskWeight ± CV risk
MounjarotirzepatideSCWeeklyEli LillyT2D
ZepboundtirzepatideSCWeeklyEli LillyWeight
FoundayoorforglipronOralDailyEli LillyWeight (newly FDA‑approved April 1, 2026)

Foundayo joins the increasingly crowded GLP‑1 space, but as the first oral GLP‑1 pill for obesity, it offers a unique option for patients who hate injections or struggle with morning‑only fasting doses.

Side Effects and Black Box: The Usual Suspects

Unsurprisingly, the side‑effect profile is classic GLP‑1: nausea, vomiting, diarrhea, constipation, abdominal pain, decreased appetite, and dyspepsia. As with all GLP‑1 agents, watch for dehydration, hypoglycemia when combined with insulin or sulfonylureas, and gallbladder disease.

The Black Box warning is also standard across the class: risk of thyroid C‑cell tumors in rodents. Foundayo is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN 2, and patients should be taught to report any new neck mass, hoarseness, or dysphagia.

Take‑Home for the Busy Cardiologist

Foundayo is not a “magic” pill, but it is another lever we can pull for patients with obesity who are ready to partner with us on lifestyle, diet, and long‑term cardiovascular health. For many, an oral, once‑daily GLP‑1 with no food or water restrictions may be the difference between this regimen and no regimen at all.

As cardiologists, our job is not just to manage stents and EF; it’s to help patients live healthier, leaner, and longer. Foundayo is one more small, cute, but potentially powerful tool in that mission.